key: cord-0912744-6kcvt9w0
authors: Mykytyn, Anna Z.; Breugem, Tim I.; Riesebosch, Samra; Schipper, Debby; van den Doel, Petra B.; Rottier, Robbert J.; Lamers, Mart M.; Haagmans, Bart L.
title: The SARS-CoV-2 multibasic cleavage site facilitates early serine protease-mediated entry into organoid-derived human airway cells
date: 2020-09-07
journal: bioRxiv
DOI: 10.1101/2020.09.07.286120
sha: 27ee7cf41be276296992fc809a32305a0b1de13a
doc_id: 912744
cord_uid: 6kcvt9w0

After the SARS-CoV outbreak in 2003, a second zoonotic coronavirus named SARS-CoV-2, emerged late 2019 in China and rapidly caused the COVID-19 pandemic leading to a public health crisis of an unprecedented scale. Despite the fact that SARS-CoV-2 uses the same receptor as SARS-CoV, transmission and pathogenesis of both viruses seem to be quite distinct. A remarkable feature of the SARS-CoV-2 spike is the presence of a multibasic cleavage site, which is absent in the SARS-CoV spike. The viral spike protein not only attaches to the entry receptor, but also mediates fusion after cleavage by host proteases. Here, we report that the SARS-CoV-2 spike multibasic cleavage site increases infectivity on differentiated organoid-derived human airway cells. Compared with SARS-CoV, SARS-CoV-2 entered faster into the lung cell line Calu-3, and more frequently formed syncytial cells in differentiated organoid-derived human airway cells. Moreover, the multibasic cleavage site increased entry speed and plasma membrane serine protease usage relative to endosomal entry using cathepsins. Blocking serine protease activity using the clinically approved drug camostat mesylate effectively inhibited SARS-CoV-2 entry and replication in differentiated organoid-derived human airway cells. Our findings provide novel information on how SARS-CoV-2 enters relevant airway cells and highlight serine proteases as an attractive antiviral target. Significance Statement Highly pathogenic coronaviruses have spilled from animals to humans three times in the past two decades. Late 2019, SARS-CoV-2 emerged in China and was declared a pandemic by March 2020. The other two highly pathogenic coronaviruses, SARS-CoV and MERS-CoV, emerged in 2002 and 2012, respectively, but did not attain sustained human-to-human transmission. Given the high diversity of coronaviruses in animals, urbanization and increased air travel, future coronavirus pandemics are likely to occur intermittently. Identifying which factors determine pandemic potential and pathogenicity are therefore of key importance to global health. Additionally, there is an urgent need to rapidly translate fundamental knowledge to the clinic, a process that is expedited through the use of relevant cell culture systems.

site in a relevant cell culture system, using airway organoids (21) that were dissociated, seeded onto 147 collagen coated Transwell inserts and differentiated for 10-11 weeks at air-liquid interface in Pneumacult 148 ALI medium (Stemcell) . After differentiation, cultures contained ciliated cells, club cells and goblet cells 149 ( Fig. S1A-C) . Moreover, they expressed the SARS-CoV-2 entry receptor angiotensin converting enzyme 

Likewise, inserting the PRRA motif into SARS-CoV S and thereby generating a multibasic cleavage site 165 did not increase PP infectivity on Calu-3 cells (Fig. S2 ). To investigate this further, we compared the entry 166 route taken by these viruses in Calu-3 cells. For this purpose, we used inhibitors of two major coronavirus 167 entry pathways (9). Serine proteases are known to mediate early coronavirus entry on the plasma 168 membrane or in the early endosome, whereas cathepsins facilitate entry in late, acidified endosomes.

Concentration ranges of either a serine protease inhibitor (camostat mesylate; hereafter referred to as 170 camostat) or a cathepsin inhibitor (E64D) were used to assess the entry route into Calu-3 cells. Entry of 171 SARS-CoV-2 PPs was not inhibited by E64D, but could be inhibited by camostat, indicating that SARS-

CoV-2 exclusively uses serine proteases for entry into these cells ( Fig. 2B-C) . For SARS-CoV PPs, entry 7 was inhibited slightly by E64D (~10%), but camostat had a far stronger effect (~90%), indicating that 174 SARS-CoV mainly uses serine proteases to enter Calu-3 cells but that a small fraction of virions enter via 

Cell-cell fusion is facilitated by the SARS-CoV-2 multibasic cleavage site and SARS-CoV-2 is more 193 fusogenic than SARS-CoV on differentiated organoid-derived human airway cells. Next, we used a 194 GFP-complementation cell-cell fusion assay (Fig. S3 ) to determine whether entry rate was associated 195 with fusogenicity. In this assay, S and GFP-11 co-transfected HEK-293T cells fuse with GFP1-10 196 expressing Calu-3 cells, resulting in GFP complementation and fluorescence. In HEK-293T cells, 197 multibasic cleavage site containing S proteins were more cleaved than S proteins without this site (Fig. 198 3A) . We observed that SARS-CoV-2 S was more fusogenic than SARS-CoV S on Calu-3 cells 199 and in addition, the insertion of the multibasic cleavage site into SARS-CoV S increased fusion, whereas 200 8 mutations in the SARS-CoV-2 S multibasic cleavage site decreased fusion. To investigate differences in 201 fusogenicity in a relevant cell system, we infected 2D differentiated organoid-derived human airway air-202 liquid interface cultures with SARS-CoV-2 and SARS-CoV and assessed the formation of syncytial cells 203 at 72 hours post infection using confocal microscopy. Cells were termed syncytial cells when at least two 204 nuclei were present within a single viral antigen positive cell that lacked demarcating tight junctions.

SARS-CoV-2 frequently induced syncytia, whereas SARS-CoV-infected cells rarely contained multiple 206 nuclei ( Fig. 3D ; and E for quantification).

The SARS-CoV-2 multibasic cleavage site increases serine protease usage and decreases 209 cathepsin usage. The findings above indicate that SARS-CoV-2 S is more fusogenic and mediates 210 faster entry through serine proteases compared with SARS-CoV, indicating that the multibasic cleavage 211 site alters protease usage. To investigate this, cells that contain both serine and cathepsin protease-212 mediated entry should be used. Therefore, we focused on VeroE6 cells, which have an active cathepsin-213 mediated cell entry pathway, as on these cells both SARS-CoV-2 PP and SARS-CoV PP entry was 214 blocked by E64D, and not by camostat ( Fig. 4A-B) . To generate a cell line in which both entry pathways 215 are active, we stably expressed TMPRSS2 in VeroE6 cells. In these cells, SARS-CoV-2 PP entry was 216 inhibited ~95% by camostat, whereas SARS-CoV PPs were only inhibited ~35% ( Fig. 4C-D) . In 217 accordance, E64D did not block SARS-CoV-2 PP entry, while it decreased SARS-CoV PP entry ~30%.

These findings indicate that despite a functional serine protease-mediated entry pathway, a significant 219 part of SARS-CoV PPs still retained cathepsin-mediated entry whereas SARS-CoV-2 PPs only used 220 serine proteases for entry. This phenotype was found to be linked to the multibasic cleavage site as 221 SARS-CoV-2 PPs containing mutations in this site entered less through serine proteases and more 222 through cathepsins (Fig. 4E-F ). In accordance, the introduction of the multibasic cleavage site into SARS-

CoV PPs increased serine proteases usage, while decreasing cathepsin usage ( Fig. 4G-H) .

224 225 SARS-CoV-2 entry and replication is dependent on serine proteases in differentiated organoid-226 derived human airway cells. Altogether, our findings show that SARS-CoV-2 preferentially uses serine 9 proteases for entry, when present, and that the multibasic cleavage site increases fusogenicity and 228 infection of human airway cells. Hence, serine protease inhibition could be an attractive therapeutic 229 option. Therefore, we assessed whether camostat could block SARS-CoV-2 entry and replication using 230 differentiated organoid-derived human airway spheroids. In these differentiated spheroids the apical side 231 of the cells was facing outwards (Fig. 5A-B) , facilitating virus excretion into the culture medium. These that individuals can transmit the virus to others before they become symptomatic (25-29). Whether 270 differences in entry rate allow SARS-CoV-2 to spread more efficiently in the human airway compared with 271 SARS-CoV remains to be investigated. It will be interesting to assess this using authentic SARS-CoV-2 272 containing multibasic cleavage site mutations, which requires a reverse genetic system, not available to 273 this study at present. Whether cell-cell fusion also plays a role in virus dissemination needs to be 274 determined. In a cell-cell fusion assay and in organoid-derived human airway cells cultured at air-liquid 275 interface we show that SARS-CoV-2 is more fusogenic than SARS-CoV and that fusogenicity is 276 increased by the SARS-CoV-2 S multibasic cleavage site. The role of cell-cell fusion in coronavirus 277 transmission and pathogenesis has not been investigated in detail, but it could be a strategy to avoid 278 extracellular immune surveillance and may increase the viral dissemination rate in the airways in vivo.

Whether the multibasic cleavage site also affects entry into cells of other organs needs to be investigated 280 11 further. Although SARS-CoV-2 symptoms are mainly respiratory, recent reports indicate frequent 281 extrapulmonary manifestations, including but not limited to thrombotic complications, acute kidney injury, 282 gastrointestinal symptoms, and dermatologic complications (30). Of note, acute kidney injury was 283 uncommon during the SARS-CoV epidemic (31). It is unclear at this moment whether these 284 manifestations are the result of extrapulmonary viral replication.

Using VeroE6-TMPRSS2 cells that have both active serine protease-and cathepsin-mediated entry 287 pathways, we show that the multibasic cleavage site increases serine protease-mediated S activation, 288 while decreasing cathepsin-mediated S activation. This indicates that the multibasic cleavage site could 289 be an adaptation to serine protease-mediated entry. Whether this site improves S activation by any 290 protease or by serine proteases specifically remains to be tested. Encountering serine proteases first may 291 result in more plasma membrane entry over endosomal entry. More efficient fusion of multibasic motif 292 containing S proteins may be caused by increased S2' cleavage due to higher accessibility of a S1/S2 293 cleaved S compared with an uncleaved S. S1/S2 cleavage was recently shown to increase the binding of 294 S to ACE2 (32). Structural changes caused by S1/S2 cleavage may affect protease accessibility as well 295 and may increase subsequent S2' cleavage.

While mutations in the SARS-CoV-2 multibasic cleavage site decreased airway cell infectivity, they 298 increased infectivity on VeroE6 cells. Several groups have reported mutations or deletions in or around 299 the SARS-CoV-2 multibasic cleavage site that arise in cell culture on VeroE6 cells (33-35), indicating that 300 the lack of a multibasic cleavage site creates a selective advantage in cell culture on VeroE6 cells. The 301 mechanism behind this remains unknown. The increased infectivity of multibasic cleavage site mutants 302 was not observed by Hoffmann and colleagues (2020), but in that study complete cleavage motifs 303 including four amino acids N-terminally from the minimal RXXR cleavage site were exchanged between 304 SARS-CoV-2 and SARS-CoV (18). In contrast, we mutated single sites or removed/inserted only the 305 PRRA motif. Importantly, a cell culture adapted virus containing a complete deletion of the multibasic 306 cleavage site was recently shown to be attenuated in hamsters (35). These studies support our findings 12 that the SARS-CoV-2 multibasic cleavage site affects tropism, facilitates airway cell entry and show that 308 proper characterization of virus stocks is essential.

Entry inhibition has been proposed as an effective treatment option for SARS-CoV-2. Chloroquine can 311 block SARS-CoV and SARS-CoV-2 entry in vitro into VeroE6 cells (36, 37), but does not block entry into 312 cells expressing serine proteases (Calu-3 and Vero-TMPRSS2) (38). This is expected, as chloroquine 313 acts in the endosome, while the endosomal entry pathway is not utilized in serine protease expressing 314 cells. As lung cells express serine proteases, inhibitors that block endosomal entry are likely to be 315 ineffective in vivo. These findings highlight that drug screens should be performed directly in relevant cells 316 to prevent wasting resources. Our study shows that SARS-CoV-2 replication in human airway spheroids 317 infected with a high MOI is inhibited ~90% by camostat, suggesting that this drug may be effective in vivo.

Future studies assessing the efficacy and safety of camostat in animal models should be conducted. For 319 SARS-CoV, camostat improved survival to 60% in a lethal mouse model (39). In the same study, 320 inhibition of cathepsins using a cysteine protease inhibitor was ineffective, supporting a critical role for 321 serine proteases in viral spread and pathogenesis in vivo. In Japan, camostat has been clinically 322 approved to treat chronic pancreatitis, and thus represents a potential therapy for respiratory coronavirus 323 infections.

Overall, our findings indicate that the multibasic cleavage motif in the SARS-CoV-2 S protein facilitates 326 serine protease-mediated airway cell entry, increasing pandemic potential. In addition, our findings using 327 authentic SARS-CoV-2 in a relevant human airway model suggest that serine protease inhibition is an 328 effective antiviral strategy, as either a therapy or prophylaxis. (METC 2012-512) . Isolation, culture and differentiation was performed as described previously (40) 359 according to a protocol adapted from Sachs and colleagues (2019) (21). Differentiation time on air-liquid 360 14 interphase was 10-11 weeks. For this study, we used carefully dissected out bronchial material for the 361 generation of bronchial airway organoids. Bronchiolar organoids were generated from distal lung 362 parenchymal material. Tracheal stem cells were collected from tracheal aspirates of intubated preterm 363 infants (<28 weeks gestational age) (41) and cultured as described before (21). For the tracheal 364 aspirates, informed consent was obtained from parents and approval was given by the Medical Ethical 

To determine the effect of camostat on SARS-CoV-2 entry, we incubated bronchial or bronchiolar cultures 376 that were differentiated at air-liquid interface for 10-11 weeks with 100% dispase in the basal 377 compartment of a 12 mm Transwell insert. After a 10 minute incubation step at 37°C 5% CO2, dispase 378 was removed and cold 500 μL AdDF+++ was pipetted onto the apical side of the Transwell to dislodge 379 the pseudostratified epithelial layer, which was subsequently mechanically sheared by pipetting using a 380 P1000 tip. The resulting epithelial fragments were washed twice in 5 ml AdDF+++ before treatment with 381 10μM camostat, 10μM E64D or carrier (DMSO) in Pneumacult (PC) ALI medium (Stemcell) on ice for 1 382 hour. Next, fragments were infected at a MOI of 2 for 2 hours at 37°C 5% CO2 in the presence of Biotechnology). For lineage marker stainings formalin-fixed inserts were paraffin-embedded, sectioned 415 and deparaffinized as described before prior to staining (42). Samples were imaged on a LSM700 416 confocal microscope using ZEN software (Zeiss). Representative images were acquired and shown as Z-417 projections, single slices or XZ cross sections.

Immunohistochemistry was performed as described previously (42) Calu-3 cells were seeded as for entry route assays and pre-treated with 10µM E64D. After one hour, PPs 470 were added per well to achieve 1000 infected cells in the control well. At the same time as addition of 471 PPs, 10µM camostat was added into the first set of wells (t=0). DMSO was added to controls. The same 472 inhibitor was added in the next sets of wells in triplicate 2, 4 and 6 hours post infection. Plates were 473 incubated overnight at 37°C 5% CO2 before scanning for GFP signal as described above. 

A Novel Coronavirus from Patients with Pneumonia in China

Coronavirus as a possible cause of severe acute respiratory syndrome

Newly discovered coronavirus as the primary cause of severe acute 519 respiratory syndrome

Identification of a novel coronavirus in patients with severe acute 521 respiratory syndrome

Isolation of a 523 novel coronavirus from a man with pneumonia in Saudi Arabia

Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of 526 human receptor CD26

Ecoepidemiology and complete genome comparison of different strains of 528 severe acute respiratory syndrome-related Rhinolophus bat coronavirus in China reveal bats as a 529 reservoir for acute, self-limiting infection that allows recombination events

Bat origin of human coronaviruses

Coronavirus Spike Protein and Tropism Changes

Host cell proteases: Critical determinants of coronavirus 535 tropism and pathogenesis

Mechanisms of coronavirus cell entry 537 mediated by the viral spike protein

Trypsin Treatment Unlocks Barrier for Zoonotic Bat Coronavirus 539 Infection

Receptor usage and cell entry of bat coronavirus HKU4 provide insight into 541 bat-to-human transmission of MERS coronavirus

Two Mutations Were Critical for Bat-to-Human Transmission of Middle East 543 Respiratory Syndrome Coronavirus

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike 545 Glycoprotein

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Proteolytic processing of Middle East respiratory syndrome coronavirus 549 spikes expands virus tropism

A Multibasic Cleavage Site in the Spike 551 Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells

Cell entry mechanisms of SARS-CoV-2

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked 556 by a Clinically Proven Protease Inhibitor

Long-term expanding human airway organoids for disease modeling

Furin cleavage of the SARS coronavirus spike glycoprotein 560 enhances cell-cell fusion but does not affect virion entry

Viral shedding patterns of coronavirus in patients with probable severe 562 acute respiratory syndrome

Clinical progression and viral load in a community outbreak of coronavirus-564 associated SARS pneumonia: a prospective study

Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents 566 of a Long-Term Care Skilled Nursing Facility

Rapid asymptomatic transmission of COVID-19 during the incubation 569 period demonstrating strong infectivity in a cluster of youngsters aged 16-23 years outside

E64D (F) to inhibit serine proteases and cathepsins, respectively. One-way ANOVA was 664 performed for statistical analysis comparing all groups to SARS-CoV-2 PPs at the highest concentration. * 665 P<0.05. (G and H) Entry route of SARS-CoV PPs and SARS-PRRA PPs on VeroE6-TMPRSS2 cells 666 pretreated with a concentration range of camostat (G) and E64D (H) to inhibit serine proteases and 667 cathepsins

PPs at the highest concentration. * P<0.05. Error bars indicate SEM. PP = pseudoparticles

Representative experiments in triplicate from at least two independent experiments are shown

A and B) Differentiated bronchiolar (A) or bronchial (B) airway 673 spheroid cultures were infected at a MOI of 2. 16 hours (A) or 24 hours (B) post infection they were fixed 674 and stained for viral nucleoprotein (red)

Representative images are shown from two independent experiments. (C to E) Replication kinetics of 677

SARS-CoV-2 in bronchiolar airway spheroid cultures pretreated with camostat or carrier (DMSO)

Live 679 virus titers (TCID50/ml) in lysed organoids. Dotted line indicates limit of detection. (F) Replication kinetics 680 of SARS-CoV-2 in 2D tracheal air-liquid interface airway cultures pretreated with camostat or carrier 681 (DMSO). TCID50 eq. per ml in apical washes are shown. Error bars indicate SEM. H p.i. = hours post 682 infection. Two-way ANOVA was performed for statistical analysis

SARS-CoV PP SARS-CoV-2 PP SARS-CoV PP SARS-CoV-2 PP

CoV-2 PP SARS-CoV-2 multibasic cleavage site increases serine protease usage

-2 PP entry route on VeroE6-TMPRSS2 cells pretreated with a concentration range of camostat (C) and E64D (D) to inhibit serine proteases and cathepsins, respectively. T-test was performed for statistical analysis at the highest concentration. * P<0.05. (E and F) Entry route of SARS-CoV-2 PP and multibasic cleavage site mutants on VeroE6-TMPRSS2 cells pretreated with a concentration range of camostat (E) and E64D (F) to inhibit serine proteases and cathepsins, respectively. One-way ANOVA was performed for statistical analysis comparing all groups to SARS-CoV-2 PPs at the highest concentration. * P<0.05. (G and H) Entry route of SARS-CoV PPs and SARS-PRRA PPs on VeroE6-TMPRSS2 cells pretreated with a concentration range of camostat (G) and E64D (H) to inhibit serine proteases and cathepsins, respectively. One-way ANOVA was performed for statistical analysis comparing all groups to SARS-PRRA PPs at the highest concentration